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BRIEF DEFINITIVE REPORT
Mutations in COPA lead to abnormal trafficking of
STING to the Golgi and interferon signaling
Alice Lepelley1, Maria José Martin-Niclós1, Melvin Le Bihan2, Joseph A. Marsh3, Carolina Uggenti4, Gillian I. Rice5, Vincent Bondet6,7,
Darragh Duffy6,7, Jonny Hertzog8, Jan Rehwinkel8, Serge Amselem9,10, Siham Boulisfane-El Khalifi11, Mary Brennan12, Edwin Carter4,
Lucienne Chatenoud13,14,15, Stéphanie Chhun13,14,15, Aurore Coulomb l’Hermine16, Marine Depp4, Marie Legendre9,10, Karen J. Mackenzie3,
Jonathan Marey17, Catherine McDougall18, Kathryn J. McKenzie19, Thierry Jo Molina13,20, Bénédicte Neven13,21,22, Luis Seabra1,
Caroline Thumerelle23, Marie Wislez17,24, Nadia Nathan9,25, Nicolas Manel2, Yanick J. Crow1,4, and Marie-Louise Frémond1
Heterozygous missense mutations in coatomer protein subunit α, COPA, cause a syndrome overlapping clinically with type I
IFN-mediated disease due to gain-of-function in STING, a key adaptor of IFN signaling. Recently, increased levels of IFN-
stimulated genes (ISGs) were described in COPA syndrome. However, the link between COPA mutations and IFN signaling is
unknown. We observed elevated levels of ISGs and IFN-α in blood of symptomatic COPA patients. In vitro, both
overexpression of mutant COPA and silencing of COPA induced STING-dependent IFN signaling. We detected an interaction
between COPA and STING, and mutant COPA was associated with an accumulation of ER-resident STING at the Golgi. Given
the known role of the coatomer protein complex I, we speculate that loss of COPA function leads to enhanced type I IFN
signaling due to a failure of Golgi-to-ER STING retrieval. These data highlight the importance of the ER–Golgi axis in the control
of autoinflammation and inform therapeutic strategies in COPA syndrome.
Introduction
Type I IFNs are critical mediators of the antiviral immune re-
sponse induced upon detection of pathogens, principally viruses,
through the sensing of their nucleic acids by innate receptors
(Hartmann, 2017). At the same time, a tight regulation of the IFN
signaling pathway is required to prevent overactivation of the
innate immune system, inducing tissue damage and pathology.
The study of the type I interferonopathies, Mendelian diseases
characterized by chronic up-regulation of IFN and IFN-
stimulated genes (ISGs), has led to the definition of in-
nate immune sensing pathways affected in these diseases
and thereby the homeostatic mechanisms necessary to avoid
autoinflammation (Uggenti et al., 2019). These include the
degradation, modification, and compartmentalization of self-
nucleic acids to avoid their aberrant detection (Crow et al., 2006a,
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Centre-Université de Paris, Paris, France; 15Institut Necker-Enfants Malades, Centre National de la Recherche Scientifique UMR8253, Institut National de la Santé et de la
Recherche Médicale UMR1151, Team Immunoregulation and Immunopathology, Paris, France; 16Pathology Department, Trousseau University Hospital, Assistance
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2006b; Rice et al., 2012; Dhir et al., 2018; Mackenzie et al.,
2017), and the regulation of key components of the IFN signal-
ing pathway (Rice et al., 2014; Zhang et al., 2015; Meuwissen
et al., 2016). Part of the viral infection detection system, the
sensor of cytoplasmic DNA cyclic GMP-AMP synthase (cGAS)
signals through the production of cyclic GMP-AMP (cGAMP) to
activate the ER protein stimulator of IFN genes (STING) and IFN
induction through TBK1 activation and IRF3 nuclear transloca-
tion. Recent observations have highlighted the ER–Golgi axis as
important in this context, with translocation of STING from the
ER to the ER–Golgi intermediate compartment (ERGIC) and the
Golgi central to the transmission and termination of cytoplasmic
DNA signaling to IFN (Ogawa et al., 2018; Gonugunta et al., 2017;
Gui et al., 2019). Indeed, heterozygous gain-of-function muta-
tions in STING induce constitutive translocation of STING to the
ERGIC/Golgi, causing a well-characterized type I interferonop-
athy, STING-associated vasculopathy with onset in infancy (SAVI;
Liu et al., 2014; Jeremiah et al., 2014; Dobbs et al., 2015; Mukai
et al., 2016). The precise mechanisms involved in the regulation of
such trafficking, and the termination of STING signaling, remain
unclear.
In 2015, heterozygous missense mutations in COPA, encoding
coatomer protein subunit α (COPA), were described to cause an
inflammatory syndrome demonstrating lung, renal, and joint
involvement (Watkin et al., 2015). Of note, this disease is char-
acterized by variable expression and a remarkably high fre-
quency of clinical nonpenetrance (Watkin et al., 2015; Vece et al.,
2016; Jensson et al., 2017; Volpi et al., 2018; Noorelahi et al., 2018;
Tsui et al., 2018; Taveira-DaSilva et al., 2019; Patwardhan and
Spencer, 2019; Boulisfane-El Khalifi et al., 2019; Frémond et al.,
2020; Krutzke et al., 2019). COPA constitutes part of the coat-
omer protein complex I (COPI), playing a role in the retrograde
transport of cargo proteins between the Golgi and the ER and the
movement of vesicles within the Golgi (Brandizzi and Barlowe,
2013; Arakel and Schwappach, 2018; Lavieu et al., 2013). Evi-
dence of ER stress, and priming of a helper T cell 17 response,
was reported in the context of mutant COPA protein (Watkin
et al., 2015), and an increased frequency of autoantibodies led to
the suggestion that COPA syndrome was an autoimmune dis-
ease. More recently, Volpi et al. (2018) described an increased
expression of ISGs in circulating blood cells of five patients with
COPA syndrome, consistent with an autoinflammatory state
related to type I IFN. The link between mutations in COPA and
IFN induction is unknown. However, the suggested clinical
similarities between COPA syndrome and SAVI (Volpi et al.,
2018), the importance of trafficking for STING signaling, and
the involvement of COPA in the ER–Golgi axis led us to hy-
pothesize that COPA might regulate the function of STING
through intracellular transport.
Herein we provide extended evidence of up-regulation of the
type I IFN pathway in symptomatic patients carrying hetero-
zygous mutations in COPA, and document the pathological
overlap between COPA syndrome and SAVI, thereby supporting
the assignation of COPA syndrome to the type I interferonop-
athy grouping. We then define the link between COPA dys-
function and IFN signaling to be STING dependent, and demonstrate
a physical, likely indirect, interaction between COPA and STING.
Finally, we show that mutant COPA is associated with an accu-
mulation of STING in the Golgi compartment, leading us to hy-
pothesize that COPA has a role in the retrograde trafficking of
STING from the Golgi to the ER. These data highlight the im-
portance of the ER–Golgi axis in type I IFN induction, and em-
phasize the potential of therapeutic strategies targeting this axis
in COPA syndrome.
Results and discussion
COPA syndrome is characterized by persistent up-regulation
of type I IFN signaling and demonstrates pathological overlap
with SAVI
We studied nine individuals, comprising six symptomatic pa-
tients and three asymptomatic relatives from four unrelated
families, each harboring a pathogenic heterozygous missense
substitution in COPA, i.e., either p.R233H or p.D243N (Fig. 1 A,
Table S1, and Fig. S1 A). The p.R233H substitution has been
previously reported in several families (Watkin et al., 2015;
Volpi et al., 2018; Taveira-DaSilva et al., 2019; Krutzke et al.,
2019), while a substitution of the aspartate at position 243 has
been described in one family, in that case to a glycine (p.D243G;
Watkin et al., 2015; Fig. 1 A). There were six females and three
males, with amedian age of 33 yr (range, 13–55 yr), and amedian
age at disease onset (symptomatic patients) of 2.5 yr (range, 1–50
yr). COPA syndrome is characterized by clinical nonpene-
trance, and three of the nine mutation carriers in this study
were asymptomatic (Fig. 1 B; Watkin et al., 2015). Five of six
symptomatic patients demonstrated clinical and/or histopatho-
logical lung involvement (Fig. 1, B and C; Table S1; and Fig. S1
B). Renal disease was observed in two patients, while one had
arthritis and two reported arthralgia. Other features sugges-
tive of autoinflammation included myositis and macrophage
activation syndrome. Positive autoantibody titers were frequently
detected.
An overlap between the clinical features of COPA syndrome
and those observed in the well-defined type I interferonopathy
SAVI (Liu et al., 2014; Jeremiah et al., 2014; Melki et al., 2017),
which can also associate interstitial lung disease, joint involve-
ment (Liu et al., 2014; Clarke et al., 2020), and hemorrhagic
alveolitis (Tang et al., 2020; summarized in Fig. 1 B and Table
S2), suggested the possibility of shared pathological determi-
nants. Lung biopsy tissue from patient F1.P1 (COPA p.D243N),
and from a patient carrying a p.V155M STING-activating mu-
tation (Jeremiah et al., 2014), both demonstrated emphysema,
lymphoid follicles, and macrophagic alveolitis (Fig. 1 C and Fig.
S1 B), consistent with previous reports of interstitial lung disease
in SAVI (Table S3). The lymphoid infiltrate was characterized by
follicular CD20+ B cells within the nodules and lung-infiltrating
CD5+ T lymphocytes, confirmed by immunohistochemical staining
(Fig. S1 B).
The type I interferonopathies are characterized by chronic
up-regulation of IFN signaling, revealed by increased expression
of ISGs (Liu et al., 2014; Jeremiah et al., 2014; Rice et al., 2013,
2017; de Jesus et al., 2020), referred to as an “IFN signature,” and
high levels of IFN-α protein in peripheral blood (Rodero et al.,
2017). We recorded a marked and persistent IFN signature,
Lepelley et al. Journal of Experimental Medicine 2 of 16
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Figure 1. Heterozygous mutations in COPA, comparison of COPA syndrome and SAVI, and constitutive activation of the type I IFN pathway in
patients. (A) Schematic representation of COPA adapted from Watkin et al. (2015) highlighting the WD40 repeat domain, the coatomer WD40-associated
region, and the coatomer C-terminal region. Previously reported mutations (Watkin et al., 2015; Noorelahi et al., 2018; Patwardhan and Spencer, 2019) are
shown above (p.K230N, p.R233H, p.W240R, p.E241K, p.E241A, and p.D243G). The mutations carried by the patients in this study are shown below (previously
reported p.R233H and newly described p.D243N). Numbers in brackets refer to the number of families identified, mutation carriers, and asymptomatic in-
dividuals, respectively. (B) Comparison of the clinical phenotypes of SAVI and COPA syndrome according to published data (left, and see Table S2), and features
present in the patients of this study (right). Lung, kidney, skin, and joint involvement are represented in blue, green, red, and yellow, respectively. AH, alveolar
hemorrhage; asterisks represent a single patient reported in the literature (Volpi et al., 2019; Tang et al., 2020). (C) Comparison of histopathological features of
the lung of a patient with SAVI carrying a p.V155Mmutation in STING (Jeremiah et al., 2014; left) and F1.P1 (right). H&E staining showing lymphoid follicles (A.1
and A.2). Immunohistochemical staining identified a majority of CD20+ B cells within the B cell follicles (B.1 and B.2), and macrophage (CD68+) alveolar in-
filtration in the SAVI patient (C.1), and the presence of rare macrophages (CD68+ cells) within the alveoli of F1.P1 (C.2). Original magnification: ×40 (A; scale
bars, 100 µm), ×10 (B and C; scale bars, 400 µm). (D) IFN scores calculated from the median fold change in relative quantification values for a set of six ISGs
Lepelley et al. Journal of Experimental Medicine 3 of 16
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within the range seen in SAVI patients, in the six symptomatic
COPA patients on every occasion tested (one to six time points
over a period of up to 3 yr), assessed by quantitative reverse
transcription PCR (RT-qPCR) of six ISGs or the expression of 24
ISGs measured on a NanoString platform (Fig. 1, D and E). In
contrast, asymptomatic mutation carriers demonstrated no, or a
minimally elevated, IFN signature. Ultra-sensitive digital ELISA
(Rodero et al., 2017) revealed raised concentrations of IFN-α in
plasma from all symptomatic individuals (median of 217.7 fg/ml;
interquartile range [IQR], 148–1,658), with mildly increased
levels in the two asymptomatic carriers tested (median of 49.61
fg/ml; IQR, 9.809–81) compared with healthy controls (HCs;
Fig. 1 F). In contrast, the concentration of other cytokines was
normal (IL-6, IL-10) or minimally elevated (TNF-α) in the plas-
ma from patients (Fig. S1 C).
Upon induction of expression through STING activation and
phosphorylation of TBK1 and IRF3, type I IFNs trigger the ex-
pression of ISGs following binding to their unique receptor IF-
NAR, subsequently activating the kinases JAK1 and Tyk2 and the
transcription factors STAT1/2. Ex vivo flow cytometry assays
demonstrated increased levels of phosphorylated STAT1 in T
lymphocytes and monocytes from COPA patients compared with
controls (Fig. 2, A and B), confirming IFN signaling through
STAT1. We previously demonstrated that, in vitro, ruxolitinib, a
JAK1/2 inhibitor, and BX795, a TBK1/IKKE inhibitor, reduced ISG
expression in peripheral blood mononuclear cells (PBMCs) from
SAVI patients (Frémond et al., 2016, 2017). Similarly, in vitro
exposure to ruxolitinib or BX795 reduced constitutively in-
creased ISG expression in PBMCs from two symptomatic pa-
tients with COPA syndrome and an asymptomatic mutation
carrier with a (minimally) positive IFN signature (Fig. 2, C and
D). Ruxolitinib has been successfully used in the treatment of
certain monogenic type I interferonopathies (Frémond et al.,
2016; Briand et al., 2019; Sanchez et al., 2018). Indeed, given
these data, JAK1/2 inhibitors are being tried in three patients in
our study, including F2.P1, who has been receiving ruxolitinib
for >1 yr, with improvement of her severe lung phenotype
(Frémond et al., 2020).
The above data characterize COPA syndrome as a novel
monogenic type I interferonopathy, sharing clinical and histo-
pathological features with SAVI. The high degree of clinical
nonpenetrance, around 30%, in reported families segregating a
pathogenic mutation in COPA, is striking and suggests that ad-
ditional factors are required to perturb IFN signaling and clinical
disease to manifest. Importantly, IFN signaling levels in COPA
patients may enable the distinction between symptomatic and
asymptomatic status, thereby providing a tool for clinical in-
vestigation and treatment decision making. Of note, while
nonpenetrance is a feature of other type I interferonopathy
genotypes (e.g., due to gain-of-function of IFIH1; Rice et al.,
2014), our experience to date has been that such asymptomatic
individuals almost invariably demonstrate a persistent up-
regulation of ISG transcripts irrespective of clinical status
(Rice et al., 2020). The reasons for this difference remain
unclear.
COPA mutants induce type I IFN production and signaling
through STING in a dominant-negative manner
To decipher the constitutive activation of type I IFN recorded
above, we transiently transfected human embryonic kidney
(HEK) 293T cells, expressing endogenous COPA but not STING
(Watkin et al., 2015; Burdette et al., 2011), with WT STING, and
with either WT COPA or a COPA construct carrying a p.K230N,
p.R233H, p.D243G, or p.D243N pathogenic mutation (with the
p.K230N substitution having been described previously in an-
other family; Watkin et al., 2015). Enhanced phosphorylation of
IRF3 was observed in cells cotransfected with STING andmutant
COPA, as opposed to cells cotransfected withWT COPA (Fig. 3, A,
B, and F). Activation of the type I IFN pathwaywas dependent on
STING, since no phosphorylation of IRF3 was detected when any
of the mutant COPA plasmids were cotransfected with an empty
vector (EV). Consistently, we recorded a significant increase in
the expression of IFNβ transcripts in cells coexpressing any of
the four mutant COPA plasmids and STING (Fig. 3, C and G).
DNA stimulation can induce the production of IFNλ1, a type III
IFN with similar activities to type I IFN, through a Ku70-STING
complex in human primarymacrophages and cell lines including
HEK293 (Sui et al., 2017). As for IFNβ, we recorded increased
expression of IFNλ1 in HEK293T cells cotransfected with mutant
COPA and STING, as comparedwith EV (Fig. 3, C and G). Of note,
mRNA expression of both IFNβ and IFNλ1, but not of type II IFN
(IFNγ), was also higher in PBMCs from one symptomatic patient
(F4.P1) and his asymptomatic mother (F4.P3), compared with
HCs (Fig. 3 E). Finally, consistent with the positive IFN signature
recorded in patients, and the induction of IRF3 phosphorylation
and IFNβ transcription in HEK293T cells, the expression of the
ISGs ISG15 and RSAD2 was enhanced in cells cotransfected with
STING andmutant COPA, but not withWTCOPA (Fig. 3, D andH).
(Rice et al., 2013; IFI27, IFI44L, IFIT1, ISG15, RSAD2, SIGLEC1; normal <2.466) recorded in patients, as compared with 10 HCs. Red lines indicate median values.
Median values in symptomatic patients (n = 9 samples from five individuals; 16.87; IQR, 9.953–39.73) were significantly higher than in HCs (1.045; IQR,
0.5225–1.870; ***, P = 0.0002), whereas median values in asymptomatic carriers (n = 5 samples from three individuals; 1.319; IQR, 0.6865– 3.179) were
comparable to HCs (by Kruskal–Wallis test). One asymptomatic carrier (F2.P2) displayed a mildly positive IFN signature on two occasions (IFN scores above the
dotted line). (E) IFN scores calculated from the median fold change in relative quantification values for a set of 24 ISGs (see Materials and methods and Table
S4, normal <2.725) recorded in the peripheral blood of F1.P1 (sampled twice, depicted as open squares) and F4.P1 (depicted as a black square), as compared
with 27 HCs (depicted as circles). Red lines indicate median values. Data were statistically analyzed using the Mann–Whitney test (**, P < 0.01). (F) Con-
centrations of IFN-α protein assessed by ultra-sensitive digital ELISA (Rodero et al., 2017) in plasma or serum from HCs (n = 20, <10 fg/ml), and patients with
mutations in TMEM173 encoding STING (n = 17 samples from nine SAVI patients) or COPA (n = 5 samples from five symptomatic patients and n = 3 samples from
two asymptomatic carriers). Red lines indicate median values of 817.8 fg/ml (IQR, 275–3,039), 217.7 fg/ml (IQR, 148–1,658), and 49.61 fg/ml (IQR, 9.809–81),
respectively, in SAVI patients, COPA symptomatic patients, and asymptomatic carriers. Data were statistically analyzed using the Kruskal–Wallis test (**, P <
0.01; ***, P < 0.0001; ns, not significant).
Lepelley et al. Journal of Experimental Medicine 4 of 16
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To determine whether heterozygous substitutions in COPA
confer an effect through a gain-of-function or dominant-
negative mechanism, we silenced COPA in cells competent for
STING signaling to IFN, i.e., the THP-1 monocytic cell line.
shRNA knockdown of COPA was sufficient to induce IRF3
phosphorylation and increased IFNβ and ISG expression
(Fig. 4, A–D and G; and Fig. S2, A and B). This suggested that the
IFN pathway is activated by loss of COPA, and that COPA
syndrome–associated substitutions act as dominant-negative
mutations. Sensing of intracellular DNA induces the synthesis
Figure 2. Type I IFN is responsible for the constitutive induction of ISGs in COPA syndrome. (A) Flow cytometry analysis of phosphorylated STAT1
(pSTAT1) in monocytes, CD3+, CD4+, and CD8+ lymphocytes from F2.P1 compared with a HC. (B) pSTAT1 measured as in A in CD3+, CD4+, and CD8+ lym-
phocytes (Ly) and CD14+ monocytes (Mo) from COPA patients compared with a HC sampled the same day, and expressed as fold mean fluorescence intensity
(MFI) of over that of the HC. Blood from F3.P1 and F3.P3 was processed during the same experiment and compared with one HC. Data were statistically
analyzed using the Mann–Whitney test (*, P < 0.05; ns, not significant). (C and D) RT-qPCR gene expression analysis in PBMCs from three patients (F2.P1,
F3.P1, and F3.P3), after overnight culture in the absence of treatment or presence of ruxolitinib (C) or BX795 (D). Results are expressed as percentage of the
baseline elevated levels and show that IFIT1, IFI27, IFI44L, ISG15, OAS1, and RSAD2 levels decreased after in vitro treatment (except IFI27 in F2.P1) for both drugs.
Data were statistically analyzed using a one-sample t test (*, P < 0.05).
Lepelley et al. Journal of Experimental Medicine 5 of 16
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Figure 3. COPA mutants induce IFN production and signaling through STING. (A)Western blot analysis of FLAG, IRF3 phosphorylated (pIRF3) at Ser396,
total IRF3, STING, and Cofilin in whole-cell lysates of HEK293T cells cotransfected with WT STING and WT COPA or mutant COPA plasmids (K230N, D243N,
D243G) or corresponding control (EV or −) plasmids for 48 h. Representative results from four independent experiments. (B) Quantification of phosphorylated
IRF3 (at position Ser396) relative to total IRF3 expressed as fold over EV signal as observed in A. Mean ± SEM of four independent experiments, analyzed with
the Kruskal–Wallis test (**, P = 0.0069). (C and D) mRNA expression analysis assessed by RT-qPCR of IFNβ, IFNλ1 (C), and two ISGs (ISG15, RSAD2; D) in
HEK293T cotransfected with EV or WT STING and WT COPA or mutant COPA plasmids. Means ± SEM of five independent experiments, statistically analyzed
Lepelley et al. Journal of Experimental Medicine 6 of 16
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of cGAMP by cGAS, thereby activating STING to signal through
the ER–Golgi axis and induce IFN production. IFN signaling
conferred by COPA down-regulation was abrogated in both
STING and cGAS KO THP-1 cells (Fig. 4, A–E and G; and Fig. S2,
A–C). In contrast, IFN signaling was not dependent on mito-
chondrial antiviral-signaling protein (MAVS), an adaptor mole-
cule essential for cytoplasmic RNA sensing (Fig. 4, F and G; and
Fig. S2 D). KO THP-1 cell lines were functionally validated by
assessing IFNβ and ISG (IFI27 and IFI44L) expression after
stimulation with agonists of the RNA (i.e., poly(I:C)) and DNA
(i.e., herring testes DNA [HT-DNA] and cGAMP) pathways (Fig.
S2, E–G; Cerboni et al., 2017; Hertzog et al., 2020 Preprint). As
expected, STING and cGAS KO cells were normally responsive to
RNA ligand poly(I:C), contrary to MAVS KO cells. Furthermore,
MAVS and cGAS KO THP-1 cells responded normally to cGAMP
stimulation while MAVS KO cells were normally responsive to
cytoplasmic HT-DNA, in contrast to cGAS KO THP-1 cells.
These data indicate that heterozygous mutations in COPA act
through a dominant-negative mechanism, with loss of COPA
function leading to STING-dependent IFN induction. This is
in agreement with results published by Watkin et al. (2015)
showing that mutant COPA acts as a dominant-negative in re-
spect to ER homeostasis. In addition, the above in vitro data
suggest both a primary role for the (mutant) COPA–STING in-
teraction in driving disease in COPA syndrome and variable
cGAS-dependency. Specifically, overexpressed STING activated
IFN signaling in response to COPA mutants in HEK293T cells
that lack cGAS expression (Sun et al., 2013), while IFN induction
following COPA knockdown in THP-1 cells was dependent on
cGAS. The latter observation suggests a tonic level of cGAMP
production by cGAS is present in THP-1 cells, perhaps driven by
mitochondrial DNA or nuclear DNA released into the cytosol as a
result of DNA damage (Mackenzie et al., 2017; Härtlova et al.,
2015; Kim et al., 2019), or activation of nuclear cGAS by chro-
matin (Lahaye et al., 2018; Gentili et al., 2019), and is required to
activate STING. In contrast, the ability of COPA mutants to ac-
tivate IFN signaling in the absence of cGAS upon overexpression
of STING in HEK293T cells suggests an effect that overwhelms
any requirement for cGAMP, perhaps most likely STING oligo-
merization due to overexpression (Ergun et al., 2019).
COPA mutants disrupt the physical interaction with STING
COPA syndrome–associated mutations are restricted to the
WD40 domain of the protein, involved in the recognition of
dilysine motifs (KKxx and KxKxx) on cargo proteins and their
packaging into COPI-coated vesicles (Brandizzi and Barlowe,
2013; Letourneur et al., 1994; Ma and Goldberg, 2013; Fig. 1 A).
Examination of the crystal structure of the human COPA WD-
repeat domain revealed that four recurrently substituted amino
acids are located close to each other in a pair of anti-parallel
β-strands (Fig. 5 A and Fig. S3 A). A further previously re-
ported mutation (p.W240R; Noorelahi et al., 2018), and an un-
published mutation annotated as “likely pathogenic” in ClinVar
(p.A239P), mapped to the same region. Five of these six mutated
residues are located on the protein surface. Inspection of the
electron microscopy structure of the COPI coat leaf (Dodonova
et al., 2017) shows that this region of COPA is also located on the
surface of the COPI complex, and does not participate in any
interactions within the leaf (Fig. S3 A). Using molecular mod-
eling, we found that the predicted effects of disease-associated
mutations on protein stability were similar to those of annotated
variants recorded in control individuals on gnomADv2.1 (Karczewski
et al., 2019; Fig. S3 B), with only the unreported mutation
(p.A239P) predicted to moderately destabilize protein folding
(ΔΔG >1.5 kcal/mol). These data suggest that disease-causing
mutations in COPA are more likely to perturb an intermolec-
ular interaction, rather than destabilize the protein. Indeed,
normal levels of COPA protein have been previously observed
in patient material (Watkin et al., 2015), and two mutations
associated with COPA syndrome (p.E241K and p.K230N) have
been shown to confer impaired binding to proteins carrying
COPI cargo dilysine motifs (Watkin et al., 2015).
Activation of ER-resident STING requires trafficking to the
Golgi (Burdette et al., 2011; Dobbs et al., 2015), with resolution of
signaling involving further trafficking to endolysosomes and
degradation (Gonugunta et al., 2017). As part of COPI, COPA
participates in the transport of proteins from the Golgi back to
the ER, and within the Golgi compartment itself (Brandizzi and
Barlowe, 2013; Popoff et al., 2011). Thus, we hypothesized that
COPA might be involved in the sorting and recruitment of
STING to COPI-coated vesicles at the Golgi, and that mutations
in COPA may result in altered STING trafficking and sustained
activation at the Golgi. To explore this possibility, we performed
reciprocal coimmunoprecipitation (coIP) in HEK293T cells co-
transfected with COPA and STING, observing a consistent in-
teraction between WT COPA and WT STING (Fig. 5 B). We
recorded a weaker interaction when the COPA construct carried
the p.K230N mutation (Fig. 5, C and D). This was apparently not
the case when the COPA plasmid carried a mutation at position
243 (i.e., p.D243N or p.D243G). To investigate whether com-
bined substitutions of different amino acids in the WD40 do-
main could have additive effects, we also generated a COPA
using two-way ANOVA and the Dunnett’s multiple comparisons test (statistics above black lines), with results above each bar indicating the comparison of
expression in cells cotransfected with WT STING and each of the three COPA mutant plasmids compared with the cells cotransfected with EV and the
corresponding COPA mutant plasmid by two-way ANOVA with Sidak’s multiple comparisons test (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant).
(E) RT-qPCR gene expression analysis of IFNβ (type I IFN), IFNλ1 (type III IFN), and IFNγ (type II IFN) in PBMCs from one symptomatic patient (F4.P1) and his
asymptomatic mother (F4.P3), and one HC, after overnight culture in one experiment. (F)Western blot analysis of HEK293T cotransfected with WT STING and
WT COPA or mutant COPA plasmids (K230N, R233H, D243G) or EV (−) as in A. Representative results for three experiments. Results were quantified for R233H
mutant compared withWT and averaged below. Data were statistically analyzed using two-way ANOVA with Sidak’s test for multiple comparison (*, P < 0.05).
(G and H)mRNA expression analysis assessed by RT-qPCR of IFNβ, IFNλ1 (G), and two ISGs (ISG15, RSAD2; H) in HEK293T cotransfected with EV or WT STING
and WT COPA or COPA R233H plasmids. Means ± SEM of three independent experiments, statistically analyzed using two-way ANOVA and Sidak’s multiple
comparisons test (*, P < 0.05).
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construct, referred to as 3M, comprising three disease-causing
COPA substitutions located in the mutation hotspot (i.e., p.K230N,
p.R233H, and p.D243N). In this assay, we observed a decreased
interaction of COPA with STING similar to that seen with the
p.K230N substitution alone (Fig. 5, C and D). Thus, while every
mutation that we tested resulted in enhanced IFN signaling
ex vivo and in vitro, we noted differential effects on STING
binding of certain mutants, perhaps explained by a bias of our
overexpression system favoring or masking the impact of the
mutation.
Figure 4. Loss of COPA induces STING-dependent type I IFN signaling. (A) Western blot analysis of IRF3 phosphorylated at Ser396, total IRF3, COPA,
STING, and Cofilin in whole-cell lysates of control (Ctrl) or STING KO THP-1 cells transduced with an EV, a scrambled shRNA or an shRNA targeting COPA
(shCOPA_1), or non-transduced (NT; left). Data are representative of three independent experiments. Asterisk indicates unspecific band. Results for a second
shRNA targeting COPA (shCOPA_2) are shown in Fig. S2, A and B. (B) Quantification of phosphorylated IRF3 (at position Ser396) relative to total IRF3 ex-
pressed as fold over scrambled shRNA signal observed in A. Means ± SEM of three independent experiments were statistically analyzed using one-way ANOVA
and two-way ANOVAwith Sidak’s multiple comparisons test for comparison of results with shScramble vs. shCOPA_1 (**, P = 0.0026) and results in control vs.
STING KO THP-1 cells for shCOPA_1 (*, P = 0.0104), respectively. (C and D)mRNA expression analysis assessed by RT-qPCR of IFNβ (C) and two of six tested
ISGS (ISG15, RSAD2, [D]; and see Fig. S2 B) in control or STING KO THP-1 cells transduced with an EV, a scrambled shRNA, two different shRNAs targeting COPA
(shCOPA_1 and shCOPA_2), or nontransduced (NT). Means ± SEM of three independent experiments, statistically analyzed using one-way ANOVA and two-
way ANOVAwith Sidak’s multiple comparisons test for comparison of results with shScramble vs. each shCOPA, and results in control vs. STING KO THP-1 cells
for each shCOPA, respectively. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. (E and F)mRNA expression analysis assessed by RT-qPCR of IFNβ in WT or THP-
1 cells null for cGAS (E) or MAVS (F) transduced with an EV, a scrambled shRNA, or two different shRNAs targeting COPA (shCOPA_1 and shCOPA_2). Means ±
SEM of three independent experiments, statistically analyzed using one-way ANOVA and two-way ANOVA with Sidak’s multiple comparisons test for
comparison of results with shScramble vs. each shCOPA, and results inWT vs. cGAS KO THP-1 cells for each shCOPA, respectively. *, P < 0.05; **, P < 0.01; ***,
P < 0.001). (G)mRNA expression of COPA assessed by RT-qPCR in THP-1 cells control and null for STING (left), orWT and null for cGAS (middle) or MAVS (right)
transduced with an EV, a scrambled shRNA, or shCOPA_1 and shCOPA_2. Mean ± SEM of three independent experiments were statistically analyzed in one-
way ANOVA (shScramble vs. shCOPA for WT and control THP-1 cells) or two-way ANOVA (WT or control vs. THP-1 cells null for STING, cGAS, or MAVS, for
each shCOPA) with Sidak’s multiple comparisons test: *, P <0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. ns, not significant.
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Figure 5. Interaction of COPA and STING and STING localization. (A) Location of pathogenic missense mutations within the structure of the COPA WD-
repeat domain (PDB ID: 6PBG). The four mutations studied in this report are shown in red, while two further previously identified mutations are indicated in
Lepelley et al. Journal of Experimental Medicine 9 of 16
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To gain insight into the details of the above interaction, we
investigated the domains of STING involved in the interaction
with COPA. STING is an ER membrane protein containing four
transmembrane (TM) domains and N- and C-terminal portions
facing the cytosol (Ouyang et al., 2012; Shang et al., 2019). We
performed coIP assays using STING constructs lacking TM1 and
TM2 (deletion 1–82), TM3 and TM4 (deletion 83–136), all four
TM domains (deletion 1–136), or the cytoplasmic C-terminal tail
(codon-stop at position 342; Fig. S3 C). All truncations, except
the 1–136 deletion, localized to the ER (data not shown). The
interaction of COPA with 342-STOP STING was conserved,
suggesting that the physical association between COPA and
STING does not require the TBK1- and IRF3-binding C-terminal
tail of STING (Fig. S3 D). Consistently, although some binding
was retained, there appeared to be a weaker interaction in the
absence of STING TM1 and TM2, or TM3 and TM4, and we could
not detect any interaction in the absence of all four TMs (Fig. S3,
D and E).
STING does not have a typical C-terminal dilysine motif,
suggesting an indirect interaction and implicating an adaptor
protein enabling binding to the COPI complex. Given that COPA
is cytosolic (Waters et al., 1991), this would be consistent with a
dependency of the COPA and STING interaction on the TM do-
mains of STING. We considered that one possible candidate
might be the calcium sensor STIM1 (stromal interaction mole-
cule 1), which does possess a dilysine motif (Lavieu et al., 2010),
and was recently shown to act as a retention factor for STING at
the ER membrane (Srikanth et al., 2019). However, knockdown
of STIM1 did not affect the interaction between COPA and
STING (Fig. S3, F and G).
COPA mutants result in abnormal STING localization
Finally, we wanted to investigate whether COPA dysfunction
could lead to STING signaling by affecting STING trafficking.
Gain-of-function heterozygous mutations in STING lead to
constitutive activation and translocation of STING to the ERGIC/
Golgi independent of an interaction with its ligand, cGAMP
(Dobbs et al., 2015; Jeremiah et al., 2014; Cerboni et al., 2017). In
HEK293FT cells, we noted increased localization ofWT STING to
a GM130-positive Golgi location when cells were cotransfected
with p.D243G and the 3M triple mutant COPA, equivalent to the
SAVI mutant STING V155M, and to WT STING cotransfected
with cGAS to induce STING activation by cGAMP. This was not
the case with WT COPA, or when WT STING was transfected
alone (Fig. 5, E and F), suggesting that loss of COPA function led
to STING accumulation at the Golgi and activation of the IFN
pathway.
COPA (α-COP) is one of seven subunits (α, β, β9, δ, ε, γ, and
ζ-COP) of the COPI complex, described tomediate the retrograde
transport of proteins between the Golgi and the ER (Brandizzi
and Barlowe, 2013; Arakel and Schwappach, 2018), and vesicle
movement within the Golgi per se (Popoff et al., 2011; Park et al.,
2015). Protein cargoes can be recognized by COPA and the β9-
COP subunits through well-characterized dilysine motifs, thus
allowing for their packaging into COPI-coated vesicles (Letourneur
et al., 1994; Ma and Goldberg, 2013). COPI also enables the re-
trieval of escaped ER-resident luminal proteins through the
recruitment of K/HDEL receptors binding to the K/HDEL signal
of these proteins (Brandizzi and Barlowe, 2013). On the other
side of the ER–Golgi interface, coatomer complex II (COPII)
mediates anterograde, ER to Golgi, transport of proteins to be
further modified in the Golgi and/or secreted (Brandizzi and
Barlowe, 2013; Fig. 5 G).
DNA recognition by cGAS leads to production of the sec-
ond messenger cGAMP, which in turn binds to STING. After
activation and conformational changes, STING moves to the
ERGIC and Golgi (Dobbs et al., 2015) to induce type I IFN
transcription through phosphorylation of TBK1 and IRF3 (Liu
et al., 2015), a process in which COPII has been implicated
(Gui et al., 2019). In contrast, SAVI-associated gain-of-func-
tion STING mutants traffic to the ERGIC in the absence of
cGAMP stimulation (Jeremiah et al., 2014; Dobbs et al., 2015).
We observed a mutation-dependent physical interaction be-
tween COPA and STING, and enrichment of STING in the Golgi
compartment in the context of mutated COPA. One possible
explanation for these data is that STING is actively trafficked
back to the ER from the ERGIC/Golgi by COPI, and that such
trafficking is reduced due to COPA loss-of-function, leading to
magenta. Location of the pathogenic missense mutations within the structure of the COPI coat leaf is given in Fig. S3 B. (B)Western blot analysis of FLAG and
STING in proteins IP with an antibody against FLAG (IP COPA, left) or STING (right), and in whole-cell lysates (input) of HEK293T cells cotransfected with EV (−)
or WT STING and WT COPA plasmids. Data are representative of three independent experiments. (C) Western blot analysis of FLAG, STING, and β-actin in
proteins IP with an antibody against FLAG (IP COPA) and whole-cell lysates (input) of HEK293T cells cotransfected with EV (EV or −) or WT STING and WT
COPA, or with individual mutant COPA plasmids (K230N, D243N, D243G) or with a plasmid carrying three substitutions (3M: K230N/R233H/D243N). Data are
representative of three independent experiments. (D) Quantification of STING protein levels co-immunoprecipitated (STING IP) with COPA-FLAG compared
with the signal recorded in the input, as observed in C. Mean ± SEM of three independent experiments were statistically analyzed using Kruskal–Wallis test (*,
P < 0.05). (E) Representative images of STING and COPA localization in HEK293FT cells transfected with WT, mutant COPA (3M carrying three substitutions:
K230N/R233H/D243N), and STING plasmids or corresponding control plasmids (−), and transfected with cGAS or control plasmid the next day. Cells were fixed
and stained for nuclear DNA (DAPI; blue), COPA (FLAG; gray), Golgi (GM130; green), and STING (magenta). “Merge” row shows an overlay of DAPI, GM130, and
STING signals, GM130 and STING costaining being represented in white. “Merge (zoom)” depicts an enlargement of the square above. Images are repre-
sentative of three independent experiments. Scale bar, 10 µm. (F) Quantification of the ratio of STING signal localized to the GM130/Golgi compartment over
total STING signal in images as in A, for at least 10 cells per condition per experiment (one-way ANOVA with Dunnett’s correction: ****, P < 0.0001). ns, not
significant. (G) Left: DNA from pathogens and damaged cells induces the production of cGAMP by cGAS. Upon binding of cGAMP, STING translocates, in a
COPII-dependent process, to the ERGIC and Golgi, where it triggers TBK1 and IRF3 phosphorylation and subsequent IFN production. We hypothesize that
COPA, within the COPI complex, plays a role in STING trafficking after signaling, taking STING back to the ER, or on to endolysosomes/the autophagy pathway
(Gonugunta et al., 2017), and thereby leading to resolution of IFN signaling. Our data indicate that STING may be a cargo of COPI through COPA. Right: When
COPA is mutated in the cargo-binding WD40 domain, STING can no longer be sorted into COPI vesicles, and so is retained in the ERGIC/Golgi in an active state,
leading to continued IFN production. COP, coatomer protein; IB, immunoblot.
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sustained signaling (Fig. 5 G). It is also possible that COPA con-
tributes to the attenuation of IFN signaling through the move-
ment of STING through the Golgi compartment (Pellett et al.,
2013). COPA, β9-COP, and β-COP have additionally been impli-
cated in autophagy and the maturation of autophagosomes
necessary for content degradation, through the maintenance of
early endosome function (Razi et al., 2009). Although we did not
detect an accumulation of STINGwhen COPA ismutated, we also
did not observe the expected degradation of STING seen when it
signals (Gonugunta et al., 2017), leaving open the question of
disrupted STING degradation in this context. Of note, STING
trafficking and signaling can be disrupted by inhibiting the
function of ARF1, a coactivator of COPI (Dobbs et al., 2015; Gui
et al., 2019), through the de-myristoylation of ARF1 GTPase by
the Shigella effector protein IpaJ, by ARF1 GTPase activity inhi-
bition upon treatment with brefeldin A (Dobbs et al., 2015), or by
siRNA knock-down of ARF1 (Gui et al., 2019). Given our data,
these observations may reflect a function of ARF1 in mediating
IFN signaling unrelated to COPA/COPI (Sztul et al., 2019), or of
COPA unrelated to COPI/ARF1.
Summarizing, we describe STING-dependent constitutive
induction of type I IFN due to heterozygous dominant-negative
missensemutations in COPA. These data indicate a role for COPA
in STING trafficking and signaling necessary for the mainte-
nance of cellular homeostasis, and highlight the ER–Golgi axis as




Patients were recruited from the Pediatric Rheumatology
Department, Royal Hospital for Sick Children (Edinburgh,
UK), the Pediatric Pneumology Department, Trousseau Hos-
pital (Assistance Publique–Hôpitaux de Paris, Paris, France),
the Pneumology Department, Cochin Hospital (Assistance
Publique–Hôpitaux de Paris, Paris, France) and the Pediatric
Rheumatology unit, University Hospital of Lille (Lille, France).
Data relating to four patients (F2.P1, F2.P2, F3.P5, and F3.P6)
have been previously reported (Boulisfane-El Khalifi et al., 2019;
Frémond et al., 2020). We recorded clinical and laboratory data,
including lung histology when performed, as well as information
relating to IFN status. The latter included the expression of ISGs
in peripheral blood, measurement of IFN-α in serum or plasma
using an ultra-sensitive digital ELISA assay (Rodero et al., 2017),
and STAT1 phosphorylation in lymphocytes and monocytes ex-
tracted from whole blood. Measurement of cytokines other than
IFN-α was performed using ELISA. The study was approved by
the Comité de protection des personnes Ile de France II and the
French advisory committee on data processing in medical re-
search (ID-RCB: 2014-A01017-40). Consent of the parents and/or
patients, depending on age, was obtained for conducting the
experiments.
Histological analyses
Formalin-fixed paraffin-embedded lung biopsy slides of patient
1 from family 1 (F1.P1) were analyzed in comparison to equivalent
samples from a patient carrying a TMEM173-activating mutation
(Jeremiah et al., 2014). Sections underwent H&E, Giemsa, and
immunohistochemical staining, using antibodies for CD5, CD20,
CD68, and smooth-muscle actin.
IFN score (Rice et al., 2013)
Total RNA was extracted from whole blood with a PAXgene
(PreAnalytix) RNA isolation kit. RNA concentration was as-
sessed with a spectrophotometer (FLUOstar Omega, Labtech).
RT-qPCR analysis was performed using the TaqMan Universal
PCRMasterMix (Applied Biosystems) and cDNA derived from 40 ng
total RNA. Using TaqMan probes for IFI27 (Hs01086370_m1), IFI44L
(Hs00199115_m1), IFIT1 (Hs00356631_g1), ISG15 (Hs00192713_m1),
RSAD2 (Hs01057264_m1), and SIGLEC1 (Hs00988063_m1), the rela-
tive abundance of each target transcript was normalized to the ex-
pression level of HPRT1 (Hs03929096_g1) and 18S (Hs999999001_s1),
and assessed with the Applied Biosystems StepOne software v2.1 and
DataAssist software v3.01. For each of the six probes, individual
(patient and control) data were expressed relative to a single cali-
brator. The median fold change of the six genes compared with the
median of 29 previously collected HCs was used to create an IFN
score for each individual, with an abnormal score being defined as >2
SDs above the mean of the control group, i.e., 2.466.
For NanoString ISG analysis, total RNA was similarly ex-
tracted from whole blood with a PAXgene (PreAnalytix) RNA
isolation kit. Analysis of 24 genes and 3 housekeeping genes was
conducted using the NanoString customer designed CodeSets
according to the manufacturer’s recommendations (NanoString
Technologies). Agilent Tapestationwas used to assess the quality
of the RNA. 100 ng of total RNAwas loaded for each sample. Data
were processed with nSolver software (NanoString Technolo-
gies). The data were normalized relative to the internal positive
and negative calibrators, the three reference probes, and the
control samples. The median of the 24 probes for each of 27 HC
samples was calculated. The mean NanoString score of the 27
HCs +2 SD of the mean was calculated. Scores above this value
(>2.724) were designated as positive. The list of probes used in
NanoString ISG analysis is supplied in Table S4.
Quantification of IFN-α protein by Simoa assay
The Simoa IFN-α assay (Rodero et al., 2017) was developed using
a Quanterix Homebrew Simoa assay according to the manu-
facturer’s instructions, and using two autoantibodies specific for
IFN-α isolated and cloned from two APS1/autoimmune polyen-
docrinopathy-candidiasis-ectodermal dystrophy patients as de-
scribed (Meyer et al., 2016; Rodero et al., 2017). The 8H1 antibody
clone was used as a capture antibody after coating on para-
magnetic beads (0.3 mg/ml), and the 12H5 was biotinylated
(biotin/antibody ratio = 30/1) and used as the detector. Re-
combinant IFNα17/αI (PBL Assay Science) was used to produce
a standard curve after cross-reactivity testing. The limit of
detection was calculated as the mean value of all blank runs +3
SD and was 0.23 fg/ml.
Structural modeling
The effects of missense mutations on the stability of the COPA
WD-repeat domain structure (PDB ID: 6PBG) were modeled with
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FoldX (Guerois et al., 2002) using default parameters. The pre-
sented ΔΔG values were calculated as the average of 10 FoldX
replicates. The FoldX “RepairPDB” function was run before
modeling the mutations. Protein structures were visualized with
PyMol.
Cell culture
PBMCs were isolated by Ficoll-Paque density gradient (Lym-
phoprep, Proteogenix) from the blood of patients and healthy
donors. Fresh or cryopreserved PBMCs were used for the assays.
Control PBMCs were obtained from the Etablissement Français
du Sang blood bank. PBMCs were cultured at 37°C in 5% CO2 in
RPMI 1640 GlutaMax medium (Invitrogen) supplemented with
10% (vol/vol) fetal bovine serum (GIBCO). PBMCs were treated
with ruxolitinib 1 µM or BX795 2 µM. HEK 293T and 293FT cells
(ATCC) were grown in 6-, 12-, or 96-well plates at 37°C in 5% CO2
in DMEM (GIBCO) supplemented with 10% (vol/vol) fetal bovine
serum (GIBCO). Control and STING KO THP-1 monocytic cell
lines were previously generated in the Manel laboratory
(Cerboni et al., 2017). WT and cGAS KO THP-1 cells were from
InvivoGen (THP1 Dual). MAVS KO THP-1 cell lines were recently
generated in the Rehwinkel laboratory (Hertzog et al., 2020
Preprint). All THP-1 cell lines were cultured at 37°C in 5% CO2
in RPMI (Invitrogen) supplemented with 10% (vol/vol) fetal
bovine serum (GIBCO). THP-1 cells were stimulated for 24 h
with 1 µg/ml poly(I:C) (High Molecular Weight; InvivoGen),
1 µg/ml 2939cGAMP (InvivoGen), or 0.25 µg/ml HT-DNA (Sigma-
Aldrich) combined with Lipofectamine 2000 (Invitrogen), fol-
lowing the manufacturer’s instructions.
Plasmids
pCMV6-Entry vector encoding Myc-DKK-tagged human WT
COPA (Origene) was used as the parental vector for mutagenesis.
Mutant plasmids of COPA were generated via site-directed mu-
tagenesis using the Q5 kit (E0554S; New England Biolabs) ac-
cording to the manufacturer’s instructions. NEB 5-α Competent
Escherichia coli was transformed with the newly synthesized
plasmid DNA, and colonies were screened for the presence of the
desired variants (primers are shown in Table S5). The p.V155M
STING mutant was previously produced in the Crow laboratory,
from the pMSCV-hygro+ plasmid carrying theWT TMEM173 gene
(Addgene). pTRIP-SFFV-mTagBFP-2A, pTRIP-SFFV-mTagBFP2-2A
STING WT, and pTRIP-SFFV-mTagBFP2-2A STING V155M
were previously described (Cerboni et al., 2017). STING
with deletions 1–82, 83–136, 1–136, and 342stop were obtained
by overlapping PCR mutagenesis and then cloned in pTRIP-
SFFV-tagBFP-2A, resulting in plasmids pTRIP-SFFV-mTagBFP2-
2A STING del 1–82, del 83–136, and 342stop. In all final constructs,
the DNA fragments originating from the PCR and encompassing
the restriction sites used for cloning were fully verified by
sequencing. Mouse cGAS was codon-optimized, synthetized,
and cloned in pVAX1 (R-D Biotech and Invitrogen), resulting
in plasmid pVAX1-cGAS.
Cell transfection
At 70% confluency, HEK293T cells were transiently cotransfected
with 100 ng (96-well plates assays) or 1,000 ng (12-well plates
assays) of total DNA plasmid using TransIT-293 (Mirus,
MIR2700). The plasmids employed were either pCMV6-Myc-
DKK encoding WT and mutant COPA, pMSCV-hygro(+)
encoding WT or mutant TMEM173/STING variant, or pTRIP-
SFFV-mtagBFP-2A encoding WT and truncated TMEM173 (see
above), and corresponding EVs as controls. For STIM1 silencing,
HEK293T cells were transiently cotransfected with 2,500 ng (6-
well plates assays) of total DNA plasmid together with a siRNA
targeting STIM1 (reference L-011785-00-0005 from Dhar-
macon) using TransIT-X2 (Mirus, MIR6000). The plasmids
employed were pCMV6-Myc-DKK encoding WT COPA, pMSCV-
hygro(+) encoding WT TMEM173/STING, and corresponding EVs
as controls.
coIP
48 h after transfection, HEK293T cells were harvested in 0.5%
CHAPS buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA)
for FLAG IP or radioimmunoprecipitation assay (Thermo Fisher
Scientific) lysis buffer for STING IP. Extracts were incubated
overnight with 20 µg/ml of anti-FLAGM2 (Sigma-Aldrich; Table
S6) or 5 µg/ml anti-STING (R&D Systems; Table S6) antibody in
the presence of Protein G magnetic dynabeads (Invitrogen) and
the resulting complexes washed with PBS (pH 7.4), 0.02%
Tween 20, denatured, and eluted according to the manufacturer’s
instructions.
Knockdown of gene expression by short hairpin RNA
Lentiviral constructs containing shRNA targeting COPA
(TRCN0000065268, TRCN0000065269, and TRCN0000244426
for shCOPA_1 in WT, cGAS KO, and MAVS KO THP-1) were
constructed by ligating annealed oligonucleotides into pLKO.1
(TRC cloning vector, a gift from D. Root, Broad Institute, Cam-
bridge, MA; Addgene plasmid 10878), according to the RNAi
consortiumprotocol (https://portals.broadinstitute.org/gpp/public/).
pLKO.1 EVwas fromOpen Biosystems and pLKO.1 control shRNA
(nontarget, SHC016) from Sigma-Aldrich. Lentiviral vectors
carrying these constructs were produced by calcium phosphate
transfection of 293FT cells with shRNA constructs in combi-
nation with packaging vectors psPAX2, a gift from D. Trono
(École polytechnique fédérale de Lausanne, Lausanne, Switzerland;
Addgene plasmid 12260), and envelope pCMV-VSV-G (Addgene
plasmid 8454). Medium of 70% confluent 293FT in 75-cm2
flasks was changed 2 h before transfection. Calcium phosphate
precipitates were prepared by mixing 12.5 µg shRNA vectors
with 12.5 µg psPAX2 and 5 µg pCMV-VSV-G in water for a final
volume of 875 µl. 125 µl 2 M CaCl2 and 1 ml Hepes-buffered
saline 2× (50 mM Hepes, 10 mM KCl, 280 mM NaCl, 1.5 mM
Na2HPO4, pH 7.05) were sequentially added dropwise in slowly
vortexed solution. Solutions were incubated at room temper-
ature for 20 min and mixed gently with 293FT supernatant.
Medium was replaced by 7 ml of culture medium 24 h later.
Supernatants were collected, centrifuged at 1,700 rpm for
5 min, and 0.4-µm–filtered. 500,000 THP1 cells were trans-
duced with 0.5 ml lentiviral vectors, 8 µg/ml polybrene (Mil-
lipore), and 10 mM Hepes (Invitrogen) in 12-well plates, and
mediumwas replaced 24 h later. Cells were collected for analysis
4 d after transduction.
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Western blot analysis
For whole cell lysate analysis, proteins were extracted from
THP-1 and transfected HEK293T cells using lysis buffer (radio-
immunoprecipitation assay, 1% protease inhibitor, 1% phospha-
tase inhibitor). Bolt LDS Sample Buffer (4×;Novex Life Technologies)
and Bolt Sample Reducing agent (10×; Novex Life Technolo-
gies) were added to protein lysates, samples resolved on 4–12%
Bis-Tris Plus gels (Invitrogen), and then transferred to nitro-
cellulose membrane (Invitrogen). Where protein phosphorylation
status was investigated, membranes were blocked in LI-COR
buffer and primary phospho-antibodies incubated for 48 h in
the blocking solution. Otherwise, membranes were blocked
with 5% nonfat milk in TBS and primary antibodies incubated
overnight in blocking buffer supplemented with 0.1% Tween.
A list of antibodies used in this study is supplied in Table S6.
Membranes were washed and incubated with appropriate anti-
mouse or anti-rabbit secondary antibodies for 45 min at room
temperature (LI-COR). Signal was detected using the Odyssey
CLx System (LI-COR). For STING Δ1-136 revelation in coIP as-
says, Quick Western Blot kit (LI-COR) was used to label STING
antibody and avoid anti-FLAG light chain signal, according to the
manufacturer’s instructions. Comparative signal analyses were
performed using Image Studio Lite (LI-COR).
RT-qPCR quantification of gene expression
Total RNA was extracted using the RNAqueous-Micro Kit
(Ambio), and reverse transcription performed with the High-
Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Levels of cDNA were quantified by RT-qPCR using Taqman Gene
Expression Assay (Applied Biosystems) and normalized to the
expression level of HPRT1. A list of the probes used in this study
is supplied in Table S7.
Confocal microscopy
HEK293FT cells were plated on fibronectin (10 µg/ml; Sigma-
Aldrich)–coated coverslips. The next day, cells were cotransfected
with COPA and STING plasmids (1.5 µl of TransIT-293 Transfec-
tion Reagent [Mirus, MIR2704] for 0.25 µg of each plasmid in
OptiMEM [Thermo Fisher Scientific, 51985042]) or corresponding
control plasmids (pTRIP-SFFV-mTagBFP-2A or pCMV6-Entry).
The next day, cells were transfected with cGAS plasmid (pVAX1-
cGAS) or control plasmid (pVAX1; 1.5 µl of TransIT-293 Trans-
fection Reagent for 0.5 µg of plasmid). 20 h later, cells were
washed twice with PBS (GIBCO) and fixed on the coverslip by
adding 500 µl of 4% PFA in PBS buffer for 30 min at room tem-
perature. Coverslips were washed twice with PBS, and incubated
with 500 ml of fresh PBS-glycine buffer (375 mg glycine in 50 ml
of PBS) for 10 min at room temperature. After two washes in PBS,
coverslips were incubated with 500 ml of staining buffer con-
sisting of PBS, 0.2% BSA (Euromedex), 0.05% Saponin (Sigma-
Aldrich, S4521), and 10% goat serum (Sigma-Aldrich, G9023) for
30 min at room temperature. For STING, GM130, and COPA vi-
sualization, coverslips were incubated with primary antibodies
against STING, GM130, and FLAG-COPA (rabbit IgG anti-GM130 at
1:200, Abcam, ab52649; or rabbit IgG anti-GM130 at 1/100, In-
vitrogen, PA5-85643; mouse IgG2b anti-STING at 1/400, R&D
Systems, MAB7169; mouse IgG1 anti-FLAG M2 at 1/1,500, Sigma-
Aldrich, F3165) diluted in staining buffer for 1 h at room tem-
perature in the dark. Coverslips were washed four times with
staining buffer and incubatedwith secondary antibodies diluted in
staining buffer (goat anti-rabbit IgG–Alexa 546 at 1:400, In-
vitrogen, A-11010; goat anti-mouse IgG2b–Alexa 647 at 1:400, Life
Technologies, A-21242; goat anti-mouse IgG1–Alexa 488 at 1:400,
Thermo Fisher Scientific, A-21121) for 1 h in the dark. Coverslips
were washed five times with staining buffer, rinsed in water, and
mounted on slides with DAPI Fluoromount-G (SouthernBiotech,
0100–20) and dried for 20 min at 37°C. Z-stacks of images were
acquiredwith a Leica DmI8 invertedmicroscope equippedwith an
SP8 confocal unit using a 63× (1.4 NA) objective.
Image analysis
Analysis was performed on one selected focal plane per cell in a
z-stack. Images were processed and analyzed using ImageJ Fiji.
For STING/GM130 colocalization analysis, a region of interest
corresponding to the cytoplasm of each cell was drawn manu-
ally, and a mask of the Golgi was obtained using a threshold on
the GM130 channel. STING intensities were measured in both
regions. The percentage of colocalization was defined as the
percentage of STING summed pixel intensities contained inside
the Golgi region divided by STING summed pixel intensities in
the total cytoplasm region.
STAT phosphorylation ex vivo assay staining
Whole blood or ficolled PBMCs were fixed using Beckman
Coulter PerFix Expose Fixation Buffer (10 min at room tem-
perature) and then permeabilized using Beckman Coulter PerFix
Expose Permeabilizing Buffer (5 min at 37°C). Cells were subse-
quently stainedwith PE-anti-STAT1 pY701, and cell surfacemarkers
(APC-anti-CD3, BV421-anti-CD8a, Alexa Fluor 750–anti-CD14) for
1 h at room temperature protected from light. Flow cytometry
analysis was performed on a Beckman Coulter Gallios flow cy-
tometer, and results were analyzed using Kaluza software v1.3.
Statistics
Analyses were performed with PRISM software (v6 for Macin-
tosh, GraphPad Inc.) as indicated in the figure legends. A P value
<0.05 was considered significant.
Online supplemental material
Fig. S1 shows the pedigrees of patients, lung pathology of patient
F1.P1, and concentration of NF-κB–related cytokines in patients.
Fig. S2 documents further characterization of IFN signaling
upon down-regulation of COPA with a second shRNA in THP-
1 WT, STING control, cGAS KO, and MAVS KO and shows
functional characterization of KO cell lines. Fig. S3 presents data
relating to the physical interaction of COPA and STING, as well
as the effect of STIM1 silencing on the COPA–STING interaction.
Table S1 shows patient characteristics. Table S2 shows the
comparison of COPA patients from this study to those in the
literature and to SAVI patients. Table S3 summarizes the pul-
monary histopathological features of COPA patients compared
with SAVI patients. Table S4, Table S5, Table S6, and Table S7
describe the NanoString probes, cloning primers, antibodies,
and RT-qPCR primers used in this study, respectively.
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Virales (ECTZ71745), Sidaction (VIH2016126002), and Ile-de-France
Emergence. M. Le Bihan received a doctoral fellowship from
Ile-de-France ARDoc. The project was supported byMSDAVENIR
(Devo-Decode Project).
Author contributions: Conceptualization: A. Lepelley, C. Ug-
genti, N. Manel, Y.J. Crow, and M.-L. Frémond; Methodology: A.
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Härtlova, A., S.F. Erttmann, F.A. Raffi, A.M. Schmalz, U. Resch, S. Anugula, S.
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Figure S1. Pedigrees of the patients, lung pathology of F1.P1, and concentration of NF-κB–related cytokines observed in the patients. (A) Pedigrees of
the four families (F) in this study. Circles (females) and squares (males) blackened and clear with vertical lines indicate respectively symptomatic and
asymptomatic carriers of the annotated heterozygous mutation in COPA. Diagonal bars indicate deceased individuals. Arrows and asterisks indicate, re-
spectively, index cases and asymptomatic individuals screened for the mutation. Numbers inside the symbols indicate the number of individuals of the same
gender. (B) Histopathological analysis of the lung biopsy of F1.P1. (B.1–B.4) H&E and Giemsa staining showing subpleural emphysema with local interstitial
thickening of the remaining interalveolar septa (B.1 and B.2), lymphoid follicles (arrows; B.3), and mildly cellular fibroblastic foci (star), as well as mild
macrophagic alveolitis (arrow; B.4, B.5, B.6, and B.7). Immunohistochemical staining identified a majority of CD20+ B cells within the B cell follicles, scattered
CD5+ T cells in the interstitium, and the presence of rare macrophages (CD68+ cells) within the alveoli. (B.8) Anti-smooth muscle actin (SMA) staining
demonstrating normal staining of vessels and absence of myofibroblastic proliferation in the interstitium. Original magnification: ×4 (B.1; scale bar, 1 mm), ×10
(B.2, B.3, B.6, and B.7; scale bars, 400 µm), ×40 (B.4, B.5, and B.8; scale bars, 100 µm). (C) Concentrations of IL-6 protein (normal < 10 pg /ml), IL-10 protein
(normal < 10 pg /ml), and TNF-α protein (normal < 20 pg/ml) measured in the plasma of COPA patients (n = 5 samples from five symptomatic patients and n =
2 samples from two asymptomatic carriers). The dotted lines indicate the normal values. Red lines depict median values.
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Figure S2. Knockdown of COPA induces STING-dependent, MAVS-independent type I IFN signaling in THP-1 cells. (A) Left: Western blot analysis of
IRF3 phosphorylated at Ser396, total IRF3, COPA, STING, and Cofilin in whole-cell lysates of control or STING KO THP-1 cells transduced with an EV, a
scrambled shRNA, or two different shRNAs targeting COPA (shCOPA_1 and shCOPA_2, respectively lanes 5 and 6, and lanes 7 and 8), or nontransduced (NT).
Data are representative of three independent experiments. Asterisk indicates unspecific band. Right: Quantification of phosphorylated IRF3 (at position Ser396)
relative to total IRF3 expressed as fold over scrambled shRNA relative signal, statistically analyzed in one-way ANOVA (shScramble vs. shCOPA for control
THP-1 cells; **, P = 0.0026 for shCOPA_1 and **, P = 0.004 for shCOPA_2) or two-way ANOVA (control vs. STING KO THP-1 cells for each shCOPA; *, P =
0.0104 for shCOPA_1 and **, P = 0.0094 for shCOPA_2) with Sidak’s multiple comparisons test (mean ± SEM). (B)mRNA expression analysis assessed by RT-
qPCR of four out of six tested ISGS (IFI27, IFI44L, IFIT1, and SIGLEC1; see other results in Fig. 4 D) in control or STING KO THP-1 cells transduced with an EV, a
scrambled shRNA, or shCOPA_1 and shCOPA_2. Mean ± SEM of three independent experiments were statistically analyzed in one-way ANOVA (shScramble vs.
shCOPA for control THP-1 cells) or two-way ANOVA (control vs. STING KO THP-1 cells for each shCOPA) with Sidak’s multiple comparisons test (*, P <0.05; **,
P < 0.01; ***, P < 0.001; ****, P < 0.0001; ns, not significant). (C and D)mRNA expression analysis assessed by RT-qPCR of two ISGs (IFI27, IFI44L; D) in WT or
THP-1 cells null for cGAS or MAVS transduced with an EV, a scrambled shRNA, or shCOPA_1 and shCOPA_2. Mean ± SEM of three independent experiments
were statistically analyzed in one-way ANOVA (shScramble vs. shCOPA for WT THP-1 cells) or two-way ANOVA (WT vs. MAVS KO THP-1 cells for each
shCOPA) with Sidak’s multiple comparisons test (ns, nonsignificant). (E and F) mRNA expression analysis assessed by RT-qPCR of IFNβ and two ISGS (IFI27,
IFI44L) in control or THP-1 cells null for STING, cGAS, or MAVS and nonstimulated (NS) or stimulated with 1 µg/ml poly(I:C), 1 µg/ml 2939cGAMP, or 0.25 µg/ml
HT-DNA for 24 h combined with Lipofectamine (Lipo). Mean ± SEM of two (poly[I:C]) to three (cGAMP, HT-DNA) independent experiments. (G)Western Blot
analysis of cGAS, STING, and MAVS expression in THP-1 WT, STING, cGAS, or MAVS KO, and loading control Vinculin. Representative of two independent
experiments. Ctrl, control.
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Figure S3. COPI complex and physical interaction of COPA and STING. (A) Location of pathogenic COPA mutations within the structure of the COPI coat
leaf (PDB ID: 5NZR). The four mutations from this study are shown in red, and two previously reported mutations are shown in magenta. (B) Predicted effects
of pathogenic mutations and putatively benign substitutions present in the gnomAD database on protein stability, calculated with FoldX. (C) Schematic
representation of WT STING and truncated STING plasmids (i.e., Δ1-82, Δ83-136, Δ1-136, and 342stop). (D)Western blot analysis of FLAG, STING, and Cofilin in
proteins IP with an antibody against FLAG (IP COPA), and whole-cell lysates (input) of HEK293T cells cotransfected with EV (EV or −), or WT COPA and WT
STING, or truncated STING plasmids, i.e., Δ1-82, Δ83-136, and 342stop (data representative of three independent experiments). (E)Western blot analysis as in
F of proteins IP with an antibody against FLAG (IP COPA), and whole-cell lysates (input) of HEK293T cells cotransfected with EV (EV or −), or WT COPA andWT
STING, STING Δ1-136 (data representative of two independent experiments). (F)Western blot analysis of FLAG, STING, STIM1, and Cofilin in proteins IP with an
antibody against FLAG and in whole-cell lysates (input) of HEK293T cells cotransfected with EV (−) or WT STING andWT COPA plasmids and with a scrambled
siRNA or an siRNA pool targeting STIM1. Results are representative of three independent experiments. (G)Quantification of STIM1 silencing assessed by mRNA
(left) and protein (right) levels measured, respectively, by RT-qPCR and Western blot 72 h after transfection. Error bars represent SDs. Results are repre-
sentative of three independent experiments. CTT, C-terminal tail.
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Tables S1–S7 are provided online. Table S1 shows characteristics of the patients. Table S2 displays a comparison of the COPA
patients in this study with those in the literature and with SAVI patients. Table S3 shows pulmonary histopathological features of
COPA patients in comparison to SAVI patients. Table S4 lists probes used for NanoString ISG analysis. Table S5 shows primers used
for site-directed mutagenesis of COPA in this study. Table S6 is a list of antibodies used in this study. Table S7 is a list of primers
used in this study for RT-qPCR.
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